

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

November 28, 2023

Robert Andrade Chief Financial Officer Fennec Pharmaceuticals Inc. PO Box 13628, 68 TW Alexander Drive Research Triangle Park, NC 27709

Re: Fennec Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed November 9, 2023
File No. 333-275452

Dear Robert Andrade:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Garrett Sleichter